Targeted drug shows promise for hard-to-treat stomach cancers
NCT ID NCT04923932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants received savolitinib and were monitored for side effects and cancer progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hopspital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can surgery for stomach or esophageal cancer cloud the mind?
- Can an immunotherapy combo shrink stomach tumors before surgery?